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Abstract
Background: Maximizing efficiency in drug development is important for drug developers, policymakers, and
human subjects. Limited funds and the ethical imperative of risk minimization demand that researchers maximize the
knowledge gained per patient-subject enrolled. Yet, despite a common perception that the current system of drug
development is beset by inefficiencies, there remain few approaches for systematically representing, analyzing, and
communicating the efficiency and coordination of the research enterprise. In this paper, we present the first steps
toward developing such an approach: a graph-theoretic tool for representing the Accumulating Evidence and
Research Organization (AERO) across a translational trajectory.
Methods: This initial version of the AERO model focuses on elucidating two dimensions of robustness: (1) the
consistency of results among studies with an identical or similar outcome metric; and (2) the concordance of results
among studies with qualitatively different outcome metrics. The visual structure of the model is a directed acyclic
graph, designed to capture these two dimensions of robustness and their relationship to three basic questions that
underlie the planning of a translational research program: What is the accumulating state of total evidence? What has
been the translational trajectory? What studies should be done next?
Results: We demonstrate the utility of the AERO model with an application to a case study involving the antibacterial
agent, moxifloxacin, for the treatment of drug-susceptible tuberculosis. We then consider some possible elaborations
for the AERO model and propose a number of ways in which the tool could be used to enhance the planning,
reporting, and analysis of clinical trials.
Conclusion: The AERO model provides an immediate visual representation of the number of studies done at any
stage of research, depicting both the robustness of evidence and the relationship of each study to the larger
translational trajectory. In so doing, it makes some of the invisible or inchoate properties of the research system
explicit – helping to elucidate judgments about the accumulating state of evidence and supporting decision-making
for future research.
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Background
Maximizing efficiency across a drug development trajec-
tory is important for drug developers, policymakers, and
human subjects. Limited resources and the ethical imper-
ative of risk minimization demand both that researchers
design and plan their studies to maximize the knowledge
gained per patient-subject enrolled and that funders and
ethical review boards hold them to this standard.
Unfortunately, this standard is often not met. The infa-
mous failure of torcetrapib at phase 3 illuminated inef-
ficiencies in cardiovascular drug development [1-3]. In
cancer, the cases of sunitinib for treating hepatic cancer
and bevacizumab for treating gastric cancer were both
examples of drugs that advanced into phase 3 testing with-
out supporting phase 2 evidence [4]. Across the entire
spectrum of drug development, nearly one-third of the
drugs abandoned at phase 2 are considered failures not for
lack of efficacy, but for ‘strategic’ reasons [4]. Even within a
single company, as Pfizer’s internal review showed, almost
half of their phase 2 proof-of-concept studies (43%) failed
to test the target mechanism of action adequately [5].
These problems all contribute to the common per-
ception that the current system of drug development is
beset by inefficiencies [4,6,7], and the growing number
of calls for greater coordination across the drug develop-
ment enterprise [8-10]. Yet, there remain no systematic
approaches for representing, analyzing, and communi-
cating the efficiency and coordination of the research
enterprise. The available techniques of systematic review
and statistical meta-analysis can only tell a part of this
story – elucidating partial cross sections of the evidence
– but they do not offer any synthesis for the accumulating
state of evidence across the entire translational trajectory.
For example, a meta-analysis is well suited to identifying
trends across a series of similar trials, but it is useless for
understanding transitions between the different phases of
research. How did the research program progress from
pre-clinical to clinical studies? How did the results of
phase 1 studies compare with phase 2? What does the
failure of translation from pre-clinical to clinical tell us
about what we ought to do next? These kinds of questions
are entirely consistent with the aim of comprehensively
understanding the translational research enterprise, but
they are not questions for which a statistical meta-analysis
is helpful.
In this paper, we present a first step toward developing
a broader, more comprehensive approach to represent-
ing and understanding a translational research program:
A graph-theoretic tool for representing the Accumulat-
ing Evidence and Research Organization (AERO) within
a translational trajectory. We begin in the next section
by describing the basic methodology – the components
of the AERO model and how these are used to con-
struct an AERO graph. We then apply this tool to a case
study involving the antibacterial agent, moxifloxacin, for
the treatment of drug-susceptible tuberculosis. We close
by discussing the potential utility of our approach for
improving the organization, coordination, and efficiency
of the drug development enterprise.
Methods
The conceptual foundations of the AERO model emerged
out of work in the philosophy of science to develop a
general methodology for representing robust scientific
evidence [11]. Although there are many different dimen-
sions of robustness that figure in drug development, the
version of the AERO model we present here focuses on
elucidating just two of these: (1) the consistency of results
among studies with an identical or similar outcome met-
ric; and (2) the concordance of results among studies with
qualitatively different outcome metrics. For example, a
series of animal experiments that all show a similar effect
size for a new drug is evidence of consistency. A positive
direction of effect on both the surrogate outcome used in
a phase 2 trial and the clinical outcome used in a phase 3
trial is evidence of concordance.
The visual structure of the AERO model is a directed
acyclic graph (DAG), designed to capture these two
dimensions of robustness and their relationship to three
basic questions that underlie the planning of a transla-
tional research program: What is the accumulating state
of total evidence? What has been the translational tra-
jectory? What studies should be done next? We discuss
each of these questions in turn, showing how they are
represented in the model.
Representing the accumulating state of total evidence
The accumulating state of evidence in a drug develop-
ment trajectory is constituted by discrete experiments,
proceeding from the pre-clinical in vitro and in vivo exper-
iments to the phase 1, 2 and 3 clinical trials. In the AERO
model, we represent each experiment as a node (that is,
a vertex) arranged in a two-dimensional space: an x-axis,
representing time, and a y-axis, representing the phase of
research. The nodes are then color-coded according to the
direction of their outcome: studies in support of further
research (for example, positive results) are green, studies
against further research (for example, negative results) are
red, and studies ambivalent toward further research (for
example, inconclusive results) are yellow.
Figure 1 is an example AERO graph for a research pro-
gram with eight experiments across three phases in a
five-year span. Although this graph is incomplete, since it
does not yet include the arrows (that is, the edges) to illus-
trate the translational trajectories, it nevertheless captures
some features of the research program that are essential
to understanding the state of total evidence. For exam-
ple, we can see that the translation from animals into
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Figure 1 Consistency of results. Studies are shown as vertices. The
graph shows eight experiments across five years with some degree of
consistency evident at every phase of research: Both of the in vitro
studies, two of the three in vivo, and two of the three phase 1 studies
were positive. There is also some inconsistency within in vivo (β1) and
phase 1 (γ2); nevertheless, the accumulating state of evidence is
largely positive and the transitions between phases appear relatively
smooth.
humans (that is, in vivo into phase 1) is relatively smooth.
Two positive animal studies (β2, β3) suggest a potential
for efficacy in humans and two positive phase 1 studies
(γ1, γ3) suggest a well-tolerated drug. There is also evi-
dence of consistency at each phase (α1 and α2, β2 and β3,
γ1 and γ3). Given that consistency between experiments
serves to verify findings and control for biases or ran-
dom errors, which may distort the results of any single
experiment, this is a desirable feature for the system to
have.
Figure 1 also shows some evidence of concordance. The
overall trend of the experimental findings is largely posi-
tive across each phase. With the exception of one negative
in vivo study and one inconclusive phase 1 study, the
results have all been favorable to further research. This
degree of concordance is another desirable feature of the
system. Depending upon the predictive power of the ani-
mal model, this pattern of robust results provides good
reason for thinking that the experimental agent may be
efficacious and safe.
Finally, assuming that β2 is later than α2 and γ1 is later
than β3, we can see that there was a de facto threshold of
two positive studies at each phase before proceeding to
the next. These thresholds between phases are an impor-
tant property of the translational trajectory, representing
critical (and often expensive) decision points: When is the
pre-clinical evidence sufficient to initiate human trials?
When is the phase 2 evidence sufficient to justify a piv-
otal phase 3 trial? Many translational failures (like those
mentioned above) can be understood as the result of poor
or inappropriate thresholds, wherein the evidence was not
sufficiently mature to warrant advancing a candidate to a
later phase of research.
One plausible way to set phase thresholds is to require
a certain number of positive studies at each phase before
proceeding to the next. Indeed, the US FDA’s licensure
requirement for two positive phase 3 trials can be thought
of as just such a threshold. However, two positives is not
the only viable threshold. For example, a certain number
of negative studies within a phase could require either that
an agent be sent back to an earlier phase or abandoned
entirely. It may also be reasonable to require that there is
a sufficient number of both positive and negative studies
at each phase – the positive studies supporting the effi-
cacy of the therapeutic ensemble for clinical translation
and the negative studies supporting a theoretical evidence
base that directly informs clinicians about how the exper-
imental agent should not be used [12]. Leaving aside the
question of which phase threshold to use, either in gen-
eral or for some specific research domain, it is sufficient
for the purposes here to observe that the AERO graph has
the virtue of rendering each of these thresholds visually
explicit.
Representing the translational trajectory
In Figure 2, we expand on Figure 1, introducing three
phase 2 studies as well as arrows between studies. The
arrows represent more precisely the sequence of studies
Figure 2 Concordance in a trajectory. Edges show the intellectual
lineage. The graph shows eleven experiments across six years. The
edges between studies represent the intellectual lineage between
them and illustrate the translational research trajectories. Some
trajectories are perfectly concordant (for example,
α1 → α2 → β3 → γ3 → δ2), while others show discordance (for
example, α1 → β1 or α1 → α2 → β2 → γ1 → δ1). The phase 2
studies are also highly inconsistent (that is, one positive, one negative,
and one inconclusive study), indicating a relatively rough transition
into this phase. Given that phase 2 was initiated after only one
positive phase 1 trial, this may indicate that the threshold of evidence
used to transition into phase 2 is too low and ought to require at least
some degree of consistency.
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and capture the intellectual lineage across the transla-
tional trajectory. For example, a phase 2 study that uses
the same dosage identified in a phase 1 study should be
connected by an arrow leading out from the phase 1 node
and into the phase 2 node (for example, γ1 to δ1). Similarly,
a phase 1 human pharmacokinetic and pharmacodynamic
study should be connected to the prior in vivo study that
identified the effective blood concentration (for example,
β3 to γ2 and γ3). Borrowing terminology from the lan-
guage of graph theory, we refer to studies downstream in
the intellectual lineage as ‘children,’ and studies upstream
as ‘parents’ (we will have more to say about how parentage
is established, when we discuss the example in the next
section).
This additional structure enriches judgments about
consistency and concordance. Where before we could
only suggest concordance by the number or ratio of pos-
itive results at each phase, now we can track a discrete
translational trajectory. For example, the trajectory from
α1 to α2 to β2 to γ1 is a sequence of four positive studies
across three phases. Each of these studies built on the evi-
dence in the prior study, and each showed a concordant
result.
Notice, however, that the story of this trajectory gets
more complicated when we follow it into phase 2. The
first phase 2 study, δ1, was negative, despite following up
the evidence from γ1. But negative results are not neces-
sarily uninformative results. Thus, as the figure shows, a
later positive phase 1, γ3, built upon δ1, and eventually led
(in conjunction with β3), to the positive phase 2 result in
δ2. The complete story of this trajectory, while not one of
perfect concordance or consistency, can nevertheless be
described as favorably robust overall.
Figure 2 also reveals that there was only positive phase
1 study (γ1) before phase 2 research began (that is, γ3
is subsequent to δ1). Again, this represents a de facto
(if not explicit) judgment about the minimum thresh-
old of evidence necessary to justify proceeding to the
next phase. Since consistency requires at least two exper-
iments, advancing into the next phase of research on
the basis of only one experiment means that this min-
imum threshold included no evidence of consistency at
the immediately preceding phase. For exactly the same
reasons that consistency is desirable, failing to have con-
sistency before proceeding to a subsequent phase is, in
general, an undesirable feature of a research system: No
verification of findings, no control for bias or random
error. While a single, well-designed study may be suffi-
cient, under particular conditions, to advance an inter-
vention, the recent failed attempts by Bayer [13] and
Amgen [14] to reproduce earlier findings demonstrates
the dangers with such an approach.
Finally, we should point out the orphaned study, δ3.
This node has no arrows leading into it, reflecting an
experiment that is not directly justified on the basis of
prior evidence within the research program. Although the
general rule is probably to avoid conducting such stud-
ies, there may at times be reasons to draw on evidence or
study designs that are external to the current research pro-
gram. For example, the experiment may be largely based
on analogical reasoning, drawing on evidence with a dif-
ferent drug or a different indication (the phase 3 trials
of sunitinib and bevacizumab alluded to above could be
described in just this way). The AERO graph makes this
design choice explicit – the prudence of which will have to
be judged by the fruitfulness of the subsequent research.
Planning the next step
The final, and perhaps most important, question we want
to address with the AERO graph is: ‘What study should be
done next?’ Given the state of accumulating evidence and
the current trajectory, what should be the next investiga-
tion(s)? In Figure 3, we have added a single, negative phase
3 study, ε1, following the trajectory from δ2. We have also
added two blue-lined nodes to represent the contemplated
next steps.
Herein lies the real power of the AERO graph: In debat-
ing what study should come next, the visualization can
sharpen the judgments of researchers, who can now pin-
point the precise translational trajectory or subset of the
trajectory that they think ought to inform future research.
Figure 3 Planning future studies. The graph shows twelve
completed experiments across six years along with two
contemplated future studies, a fourth phase 2 trial (δ4) and a second
phase 3 trial (ε2). A phase 3 trial (ε1) was initiated following the sole
positive phase 2 study (δ2). The result of this phase 3 trial was
negative, discordant with the earlier phase 2 result. Now researchers
must decide which study (or studies) to do next: Trust that the
accumulated evidence is still sufficient to motivate another phase 3
or return to phase 2 in search of greater consistency and a potential
explanation for the discordance between δ2 and ε1.
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For example, let us suppose that ε1 was negative for lack
of clinically significant effectiveness. A researcher could
argue that despite the negative result, there is still a largely
positive trend (seven out of twelve studies) across the
entire trajectory, the drug is very well tolerated (no neg-
atives at phase 1), and the inconsistency across phase 2
studies has been instructive in suggesting a novel variation
on the dosage and schedule that ought to be evaluated in
a subsequent phase 3 trial. Yet, a different researcher may
look at the same graph, identify a mechanism of action
common to the inconclusive and negative studies that
could explain these results, and recommend δ4 to test this
hypothesis in a less costly, phase 2 trial.
The purpose of the AERO graph is thus not to replace
this kind of critical thinking or eliminate disagreement
about the state of total evidence. Indeed, researchers may
even disagree about whether a particular study ought to be
represented as positive or negative. Rather, the purpose of
the AERO graph is to sharpen this disagreement by clari-
fying the state of evidence and translational trajectory. In
other words, the prudent course of action within a clin-
ical research program cannot be derived from the state
of evidence. The decision of what to do next requires a
negotiation between the practical, pragmatic, ethical, and
epistemic issues at play. The representational features of
the AERO model help to make the epistemic aspects of
this judgment explicit.
Results
In its Global Plan to Stop TB 2011–2015, the Stop TB
Partnership emphasizes the need for improving coordina-
tion across the entire development and testing trajectory
[10]. Moxifloxacin, an antibacterial agent in the fluo-
roquinolone family, is one of the new candidate drugs
in their pipeline. However, as of 2010, the tuberculo-
sis research community was confronted with a series of
inconsistent results across five phase 2 studies with mox-
ifloxacin, and disagreed about whether the state of total
evidence supported moving on to conduct phase 3 tri-
als. The results we present in this section are based
on our presentation at the Tuberculosis Trials Consor-
tium’s semi-annual meeting in October 2011, where we
presented an AERO graph of moxifloxacin’s translational
trajectory to help broker this dispute.
Representing the evidence
Inclusion
Table 1 summarizes the results of 19 studies evaluat-
ing moxifloxacin for the treatment of drug-susceptible
tuberculosis between 1998 and 2009. These studies were
included based on a hand search through the citations
of the published phase 2 trial reports. This list was then
cross-referenced with a PubMed search using the terms
‘moxifloxacin’ and ‘tuberculosis;’ filtered by clinical trials.
Table 1 Summary of moxifloxacin-TB studies
In vitro Year Key Outcome Children
Ji et al. [15] 1998 u1 Positive v1
Gillespie et al. [16] 1999 u2 Positive w1, w2
Shandil et al. [17] 2007 u3 Positive w5, w6
In vivo
Ji et al. [15] 1998 v1 Positive v2
Miyazaki et al. [18] 1999 v2 Positive v3, w1
Lounis et al. [19] 2001 v3 Positive v4
Yoshimatsu et al. [20] 2002 v4 Inconclusive v5
Nuermberger et al. [21] 2004 v5 Inconclusive u3, w3, w4
Phase 1
Gosling et al. [22] 2003 w1 Positive v5
Pletz et al. [23] 2004 w2 Positive v5
Gillespie et al. [24] 2005 w3 Negative x1
Johnson et al. [25] 2006 w4 Positive x1, x2
Nijland et al. [26] 2007 w5 Negative –
Peloquin et al. [27] 2008 w6 Inconclusive x4
Phase 2
Burman et al. [28] 2006 x1 Negative w5, w6, x3, x4
Rustomjee et al. [29] 2007 x2 Positive x3
Conde et al. [30] 2009 x3 Positive x5
Dorman et al. [31] 2009 x4 Negative –
Wang et al. [32] 2009 x5 Positive –
While this method is less rigorous than a complete sys-
tematic review, it is sufficient for the illustrative purposes
of this paper. Further development on harmonizing the
AERO model with the methods of systematic review is
underway.
Extraction
The ‘year’ in Table 1 refers to the year of publication. The
‘key,’ generated sequentially by phase, refers to the corre-
sponding node in Figure 4. The outcome was extracted
from the published manuscript, based on the direction of
the observed effect, the authors’ recommendation for fur-
ther research, and any expressed qualifications or reser-
vations. The studies listed as ‘children’ are based on a
transitive reduction of the total network of citations,
reconstructed to represent the historical translation of
evidence as accurately as possible.
Non-positive outcomes
We acknowledge that the inconclusive status of the two
in vivo studies is debatable. Despite evidence of efficacy,
we nevertheless classified Yoshimatsu et al. as inconclu-
sive due to the authors’ concerns about toxicity at the
recommended dosage [20]. Nuermberger et al. did not
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Figure 4 Complete AERO graph for moxifloxacin in an anti-tuberculosis regimen. The graph shows 19 completed experiments across 12 years
along with four contemplated future studies. The overall trend of study results was positive until the transition into phase 2 (x1), when significant
discordance (for example, w4 → x1 and w6 → x4) and inconsistency (that is, negative results in x1, x4 vs. positive results in x2, x3, x5) began to
emerge. Researchers must now decide how to proceed in the face of an equivocal state of total evidence: Investigate mechanisms of discordance
between animal models and human trials (A); investigate drug interactions (B); further investigate efficacy and evaluate predictivity of specific phase
2 trial designs (C); or proceed to a decisive phase 3 effectiveness trial (D).
show an improvement on their primary outcome (time-
to-culture-negative), but did show a dramatic increase in
early potency when moxifloxacin was substituted for iso-
niazid, one of the drugs in the standard regimen [21].
Gillespie et al. showed no difference in the early bacte-
ricidal activity between moxifloxacin and isoniazid [24].
Nijland et al. showed that moxifloxacin plasma concen-
trations are reduced when it is administered with isoni-
azid and rifampicin [26]. Peloquin et al. showed favorable
population pharmacokinetics with moxifloxacin, but lev-
ofloxacin had the most favorable profile in their study [27].
Both Burman et al. and Dorman et al. showed no improve-
ment in the time-to-culture-negative when moxifloxacin
was substituted into the standard regimen for ethambutol
and isoniazid, respectively [28,31].
Visual representation
Figure 4 is the complete AERO graph based on the infor-
mation in Table 1 and the possible future studies, A . . . D.
It was rendered using the tikz vector illustration pack-
age for LaTeX. All of the non-straight edges were shaped
manually in order to aid visual comprehension. The edge
between u1 and v1 is not an arrow because these two
studies are published in the same report.
Analysis
The first thing to notice about Figure 4 is how much
messier is the picture of an actual translational research
program compared to the toy example we discussed
above. One immediate advantage of the AERO graph is
that it illuminates the point about translational research:
It is not a linear process, but a complex network of over-
lapping investigation types. Phases can even be repeated,
as when evidence from a downstream phase is used to
inform a subsequent upstream investigation (for example,
v5 → u3).
But however descriptively accurate is this complexity,
there is a prescriptive question about how organized and
systematic a research program in translational medicine
ought to be. Is this overlapping web of studies an intrin-
sic part of translational medicine? Or can it be made
more orderly, with one study and one phase proceeding
after another without the need to backtrack? While we
will not take up this intriguing question here, it is worth
pointing out that the AERO model facilitates such an
inquiry.
So what can we now say about moxifloxacin’s transla-
tional trajectory? Across the entire trajectory, the trend is
largely positive, with a 3:1 positive to negative ratio. There
is also evidence of consistency at every phase and no neg-
ative results in the pre-clinical studies. Although to our
knowledge there was no explicit evidence threshold estab-
lished for this trajectory, we can nevertheless observe that
for both the pre-clinical to clinical and phase 1 to phase 2
transition, the de facto threshold is three positive studies.
Thus far, these would all seem to be encouraging prop-
erties. In fact, prior to the first negative phase 2 study in
2006, the evidence for moxifloxacin was overwhelmingly
favorable.
After 2006, significant inconsistency and discordance
emerges. Two of the five phase 2 studies, x1 and x4, are
negative and show discordance with the earlier phase 1
and pre-clinical outcomes. Indeed, there is a subset of the
total trajectory, proceeding through w3 to x1 and then w5
and x4, that is both consistently and concordantly nega-
tive. This underscores the fact that robustness is not only
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a property of positive results. Results can also be robustly
negative.
Yet, one negative sub-trajectory is not necessarily fatal
for the whole translational trajectory. In this case, we can
see an overall trend toward positive outcomes, but it is
not obvious that this trend is sufficient to justify a phase
3 trial. Therefore, we now consider how the AERO graph
can sharpen arguments for or against each of the four
proposed future studies.
A: The argument in favor of A, another in vivo study,
is supported by the striking discordance between the
pre-clinical and clinical results along the following sub-
trajectory:
. . . v5 → w3 → x1 → x4 ⇒ A
Given that the in vivo models and phase 2 trials are both
evaluating an efficacy endpoint, rather than the safety,
pharmacokinetic, or early activity endpoints evaluated in
phase 1, the discordance between in vivo and phase 2,
combined with phase 2 inconsistency, casts a reasonable
doubt on the predictive power of the animal models. For
example, Dorman et al.’s (x4) hypothesis, comparing the
replacement of moxifloxacin for isoniazid in the standard
regimen, was informed by Nuermberger et al.’s (v5) find-
ing in a murine model. The failure to translate this result
supports revisiting the in vivo design and re-evaluating the
import of in vivo experiments.
But we should note that pursuing another in vivo study
does not necessarily invalidate the prior phase 1 or phase 2
results. Those studies can still be internally valid and their
evidence can remain reliable and informative in future
analyses. The rationale in favor of another animal study
is that it may be more productive or efficient in the long
term to try and explain the discordance between some
of the extant animal and human results, rather than sim-
ply continuing to test moxifloxacin-containing regimens
in humans.
B: The argument in favor of B, another phase 1 study,
is supported by the inconsistencies at phases 1 and 2. In
addition to the above sub-trajectory, which tracks the neg-
ative results at phase 2, this line of reasoning adds a second
trajectory of emphasis:
. . . v5 → w3 → x1 → x4 ⇒ B
. . . x1 → w5 ⇒ B
These sub-trajectories suggest a need to better under-
stand the pharmacokinetic properties of moxifloxacin
when used with the other drugs in the standard anti-
tuberculosis regimen. Nijland et al.’s (w5) finding that
some combinations with moxifloxacin produce lower
plasma concentrations relate directly to this point.
C: The argument in favor of C, another phase 2 trial,
emphasizes differences in experimental design across
the phase 2 studies, supported by the following sub-
trajectories:
. . . v5 → w4 → x1 → x3 → x5 ⇒ C
. . . x1 → x4 ⇒ C
. . . x2 → x3 → x5 ⇒ C
Just as we discussed a robustly negative sub-trajectory,
a researcher could emphasize the robustly positive sub-
trajectory and claim that if any doubts about moxi-
floxacin’s potential efficacy remain, that these ought to be
eliminated by another, rigorous phase 2.
Importantly, the justification for C turns, in no small
part, on assumptions about the purpose of the phase 2
trial and the threshold of evidence for proceeding to phase
3. If phase 2 trials are supposed to limit the number of
candidate interventions for phase 3 strictly, then it may
be reasonable to require at least a 2:1 positive-to-negative
trial ratio, for example, before advancing. In which case,
C seems a reasonable option. If, however, phase 2 trials
are only supposed to rule out dangerous candidates, then
three positive trials is arguably sufficient, and therefore, C
would seem to be unnecessary.
D: This leads to the argument for D, a phase 3 trial, which
could be justified on the grounds that moxifloxacin has
been evaluated in three positive phase 2 trials, has not
been ruled out as a novel candidate for inclusion in an
effective anti-tuberculosis regimen, and is supported by
the sub-trajectory:
. . . v5 → w4 → x2 → x3 → x5 ⇒ D
As we have already mentioned, the overall picture of mox-
ifloxacin’s trajectory is largely positive – not perfect, but
arguably robust. Therefore, it may be reasonable to pro-
ceed to phase 3, despite the inconsistency across phase
2. Indeed, we should acknowledge here the REMox-TB
trial (NCT00864383), an in-progress phase 3 trial evaluat-
ing a moxifloxacin-containing regimen for the treatment
of drug-susceptible tuberculosis. The results of this trial,
although not yet available, can be understood, in part,
as an empirical test of this line of reasoning. A positive
and reproducible finding in the REMox-TB trial would
be evidence that the AERO graph of Figure 4 reflects a
promising trajectory. Inversely, a negative finding should
cast doubt on the idea that such a trajectory is robust
enough to justify a phase 3 trial.
Summary
Whichever direction is ultimately selected for future
research, the AERO model can be dynamically updated in
light of those new study results as they become available.
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For example, suppose that moxifloxacin researchers were
to pursue both options A and C – another animal study
and another phase 2 trial, respectively. And assume fur-
ther that both of these turn out to be positive. This could
potentially show that the researchers now better under-
stand the predictive relationship between the animal and
human models and perhaps finally tip the balance of phase
2 evidence clearly in favor of a moxifloxacin regimen.
Yet, even before these studies are executed, researchers
could use the AERO graph to strategize about future states
of evidence. In contemplating option B, another phase 1
trial, one might reasonably question if that result, what-
ever it turns out to be, would be informative and useful
enough to justify the opportunity cost of not pursuing A,
C or D.
We should also acknowledge that these alternative
research strategies are neither exhaustive nor mutually
exclusive. A well-funded research program may be able
to pursue all of these and other options simultaneously.
The aim in this section is simply to show how the AERO
graph can help to clarify and sharpen the rationale for the
various possibilities and in so doing, aid decision-making
about the directions for further research.
That said, the more fundamental questions elucidated
by the moxifloxacin trajectory – calling into question the
predictive value of the animal model, reconsidering the
purpose for phase 2, and the appropriate thresholds of
robustness at each phase transition – should not be over-
looked, even if the decision is made to proceed to a phase
3 trial. Part of what Figure 4 illustrates is that there are
many unanswered questions about moxifloxacin’s trajec-
tory and the underlying causal relationships, and until at
least some of these are addressed, a phase 3 trial, whatever
its outcome, will be less informative that it could be, and
hence, reflect an inefficient research strategy over the long
term.
Discussion
Stepping back from this specific case study, there are a
number of possible elaborations and applications of the
AERO modeling approach that are worth discussing. To
begin with, the color-coding we presented here, which
classifies studies as positive, negative, or inconclusive, has
significant virtues of simplicity and ease of interpretation,
but this is far from the only option. For example, a contin-
uous shading scale could be used to represent the effect
size or precision of each study; or a five-point ordinal scale
could be used, corresponding to the region of posterior
interval. The fundamental structure of the AERO model
is the directed acyclic graph with study-type strata; the
other graphical properties can be extensible in any way
that supports decision-making.
The AERO graph can also be thought of as reflect-
ing the maturity of causal knowledge within a given
research domain. A robust field of mostly green nodes
would suggest that investigators have full command of the
mechanisms in the causal system, whereas a field of pre-
dominantly red or yellow nodes would suggest utter lack
of contact with the causal factors. A pattern of pre-clinical
green that consistently turns to red in clinical translation
should cast doubt on the validity of pre-clinical models.
A thin thread of green would perhaps suggest just a lucky
find, while an evenly balanced network of green and red
nodes would suggest a new, emerging domain with which
investigators may have only a limited understanding.
This relates to another extension of the approach – com-
paring and contrasting multiple trajectories. We could
see such a comparative analysis being useful in a number
of ways: For example, the AERO graph of a successfully
translated agent could be used as the model for how new
agents in a treatment domain ought to be vetted; or a
population of AERO graphs could elucidate systematic
differences in efficiency or risk and benefit across different
research domains.
Looking ahead to envision the potential utility of the
AERO model, particularly as a means to improve the effi-
ciency and coordination of the drug development enter-
prise, we believe that publications and protocols could
both benefit from including an AERO graph. Just like
other kinds of visual tools, such as Thorpe et al.’s PRE-
CIS graph [33] or Langan et al.’s graphical augmentation to
the meta-analytic funnel plot [34], serve to aid judgments
about the quality and direction of evidence, so too can the
AERO model help to make invisible or inchoate properties
of the research system explicit.
Indeed, AERO graphs could provide a convenient check
for investigators, institutional review boards, journal edi-
tors, and physicians. The comprehensibility of the repre-
sentation allows for anyone even modestly familiar with
a particular domain to be able to compare and contrast
alternative representations. As a consequence, a report
that ignores a substantial portion of the available evi-
dence can be more easily detected, since its represen-
tation will differ dramatically. This is not to contradict
what we claimed earlier about disagreement, as different
researchers may have equally legitimate interpretations of
their field. However, the apparent contrast between inter-
pretations of the evidence will demand an explanation for
why the authors represented the field in one way rather
than another.
Conclusion
The AERO model provides an immediate visual repre-
sentation of the number of studies done at any mode,
depicting both the direction of evidence and the relation-
ship of each study to the larger translational trajectory.
In so doing, it helps to address the widespread con-
cerns about efficiency, coordination, and organization in
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translational medicine. To be sure, the visual represen-
tation does not capture all of the available information
about a research program. For example, the details of dif-
fering experimental designs or conduct may be relevant to
understanding failures of robustness. Just as we showed
in the previous section, the argument for one course of
action over another relies upon knowledge of these addi-
tional details about each experiment. Nevertheless, the
AERO model provides a systematic representation that
is capable of sharpening these judgments and reveal-
ing some of the existing patterns across a translational
trajectory.
We recognize that the approach we have presented here
is but a preliminary sketch. While we have applied the
AERO model to a single case study, much more work is
needed to develop the approach to its full potential. But
particularly given the stakes, thinking about ways to better
analyze and judge the structure of clinical research pro-
grams as a whole seems a vital line of inquiry. The AERO
model is one piece of this inquiry.
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